Co-Founder & CEO, Preclinical/Early Drug Discovery; SME on Protein X-ray Crystallography, Structural Biology, Biophysics, Chemistry and Structure-, Fragment and AI-Based Drug Discovery (SBDD, FBDD, AIDD).
“Why DNA Damage Response deserves renewed focus in cancer therapy” “DDR pathways are set to overcome resistance and alter treatment strategies…. now is the perfect moment to refocus on DDR, and how its potential to drive innovation in oncology could transform patient outcomes…. simultaneously targeting multiple DDR mechanisms or integrating DDR inhibitors into multimodal treatment strategies”: https://lnkd.in/gPkQrND4 #oncology #therapeutics #drugdiscovery